GlassScriptPhysician profile
Peter D Obesso
NPI 1356577787
$33,970.83
in general payments reported to CMS, 2019-2025
15 companies · $4,273 in 2025
The $4,273 reported for 2025 was more than what 92% of Sleep Medicine (Internal Medicine) providers received nationally (typical 2025 total: $447).
See the full distribution for Sleep Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $204 · 2020: $726 · 2021: $124 · 2022: $7,862 · 2023: $11K · 2024: $9,721 · 2025: $4,273.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $12K · Food and Beverage: $4,439 · Honoraria: $3,150 · Travel and Lodging: $2,219 · Consulting Fee: $1,913 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $1,275 · Education: $205.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $11,853.95 |
| Food and Beverage | $4,438.83 |
| Honoraria | $3,150.00 |
| Travel and Lodging | $2,218.70 |
| Consulting Fee | $1,913.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $1,275.00 |
| Education | $204.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $19,313.82 | 2022-2024 | Quviviq |
| Axsome Therapeutics, INC. | $7,235.33 | 2022-2025 | Sunosi, Auvelity |
| Zoll Respicardia, INC. | $2,585.14 | 2023-2025 | Remede System |
| Inspire Medical Systems, INC. | $2,201.79 | 2020-2025 | Inspire |
| Jazz Pharmaceuticals INC. | $1,176.06 | 2019-2025 | |
| Harmony Biosciences LLC | $826.45 | 2020-2024 | Wakix |
| Merck Sharp & Dohme LLC | $234.73 | 2022-2023 | Belsomra |
| Eisai INC. | $125.00 | 2019 | |
| Avadel Cns Pharmaceuticals, LLC | $88.09 | 2023-2025 | Lumryz |
| Itamar Medical INC | $64.02 | 2023 | Watchpatone |
| 3b Medical, INC. | $29.57 | 2025 | Luna |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $26.37 | 2024 | Lifevest |
| Fisher & Paykel Healthcare INC | $23.63 | 2022 | |
| Philips North America LLC | $22.91 | 2019 | |
| Pfizer INC. | $17.92 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Obesso listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.